Cargando…

Advances in Immunotherapy for Adult Glioblastoma

SIMPLE SUMMARY: Therapy failure and disease recurrence are hallmarks of glioblastoma (GBM), the most common and lethal tumor in adults that originates in the brain. Despite aggressive standards of care, tumor recurrence is inevitable with no standardized second-line therapy. Recent clinical studies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chokshi, Chirayu R., Brakel, Benjamin A., Tatari, Nazanin, Savage, Neil, Salim, Sabra K., Venugopal, Chitra, Singh, Sheila K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305609/ https://www.ncbi.nlm.nih.gov/pubmed/34298615 http://dx.doi.org/10.3390/cancers13143400

Ejemplares similares

In vitro evaluation of CAR-T cells in patient-derived glioblastoma models
por: Brakel, Benjamin A., et al.
Publicado: (2021)

A Patient-Derived Xenograft Model of Glioblastoma
por: Chokshi, Chirayu R., et al.
Publicado: (2020)

Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma
por: Tatari, Nazanin, et al.
Publicado: (2020)

SYST-26 INVESTIGATING THE FUNCTIONAL ROLE OF GPNMB IN GLIOBLASTOMA AND THE TUMOR IMMUNE MICROENVIRONMENT AND ITS TARGETED ELIMINATION USING CAR-T CELLS
por: Savage, Neil, et al.
Publicado: (2023)

GENETIC SCREENING REVEALS DEPENDENCY ON FEN1 TO RESIST TEMOZOLOMIDE IN TREATMENT-RESISTANT GLIOBLASTOMA STEM CELLS
por: Brakel, Benjamin, et al.
Publicado: (2023)

The Strange Case of Jekyll and Hyde: Parallels Between Neural Stem Cells and Glioblastoma-Initiating Cells
por: Bakhshinyan, David, et al.
Publicado: (2021)

UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA
por: Maich, William, et al.
Publicado: (2023)

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022)

BSCI-20. THERAPEUTIC TARGETING OF HLA-G IN BRAIN METASTASES
por: Singh, Sheila, et al.
Publicado: (2019)

Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations
por: Martell, Emma, et al.
Publicado: (2023)

47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES
por: Bassey-Archibong, Blessing, et al.
Publicado: (2020)

Assessing the Safety of a Cell-Based Immunotherapy for Brain Cancers Using a Humanized Model of Hematopoiesis
por: Salim, Sabra K., et al.
Publicado: (2020)

SYST-28 FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND A NOVEL TARGETABLE PTP4A2-ROBO1 SIGNALING AXIS AT GLIOBLASTOMA RECURRENCE
por: Chokshi, Chirayu, et al.
Publicado: (2023)

AUTOLOGOUS PATIENT-DERIVED CAR-TS SHOW FUNCTIONAL DEFICITS AGAINST HUMAN GLIOBLASTOMA
por: Salim, Sabra K, et al.
Publicado: (2023)

An HLA-G/SPAG9/STAT3 axis promotes brain metastases
por: Bassey-Archibong, Blessing Iquo, et al.
Publicado: (2023)

ROBO1 CAR-T CELL THERAPY FOR TREATMENT REFRACTORY BRAIN CANCER
por: Shaikh, Muhammad Vaseem, et al.
Publicado: (2023)

Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors
por: Tatari, Nazanin, et al.
Publicado: (2022)

SYST-33 GENERATION OF ALLOGENEIC CAR-T CIRCUMVENTS FUNCTIONAL DEFICITS IN PATIENT-DERIVED AUTOLOGOUS PRODUCT FOR GLIOBLASTOMA
por: Shaikh, Muhammad Vaseem, et al.
Publicado: (2023)

Advances in immunotherapy for the treatment of glioblastoma
por: Tivnan, Amanda, et al.
Publicado: (2016)

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA
por: Bakhshinyan, David, et al.
Publicado: (2021)

Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers
por: Lechpammer, Mirna, et al.
Publicado: (2022)

Immunotherapy of glioblastoma: Recent advances and future prospects
por: Yuan, Boyang, et al.
Publicado: (2022)

Current Advances in Immunotherapy for Glioblastoma
por: Mende, Abigail L., et al.
Publicado: (2021)

Advances in immunotherapy for glioblastoma multiforme
por: Mahmoud, Ahmad Bakur, et al.
Publicado: (2022)

Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults
por: Olivet, Meagan Mandabach, et al.
Publicado: (2023)

Biomarkers for immunotherapy for treatment of glioblastoma
por: Lynes, John P, et al.
Publicado: (2020)

Metabolic Barriers to Glioblastoma Immunotherapy
por: Choudhary, Nikita, et al.
Publicado: (2023)

Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
por: Segura-Collar, Berta, et al.
Publicado: (2023)

Advances in NKT cell Immunotherapy for Glioblastoma
por: Pyaram, Kalyani, et al.
Publicado: (2018)

Advances in Nanotechnology-Based Immunotherapy for Glioblastoma
por: Tang, Lin, et al.
Publicado: (2022)

Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements
por: Agosti, Edoardo, et al.
Publicado: (2023)

MicroRNA Regulation of Brain Tumour Initiating Cells in Central Nervous System Tumours
por: Garg, Neha, et al.
Publicado: (2015)

Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma
por: Matsui, Jennifer K., et al.
Publicado: (2022)

Virus-Based Immunotherapy of Glioblastoma
por: Martikainen, Miika, et al.
Publicado: (2019)

Emerging Biomarkers for Immunotherapy in Glioblastoma
por: Mensali, Nadia, et al.
Publicado: (2022)

Next Steps for Immunotherapy in Glioblastoma
por: Cao, Toni Q., et al.
Publicado: (2022)

Revealed: The spy who regulates neuroblastoma stem cells
por: Vora, Parvez, et al.
Publicado: (2014)

Brain Metastasis-Initiating Cells: Survival of the Fittest
por: Singh, Mohini, et al.
Publicado: (2014)

Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas
por: Chawla, Sanjeev, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_90ncbdi1b1ep3oh672chs279ep